Harada M - Search Results

1

Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells.

Motoshima T, Komohara Y, Horlad H, Takeuchi A, Maeda Y, Tanoue K, Kawano Y, Harada M, Takeya M, Eto M. Motoshima T, et al. Among authors: harada m. Oncol Rep. 2015 Jun;33(6):2947-53. doi: 10.3892/or.2015.3893. Epub 2015 Apr 2. Oncol Rep. 2015. PMID: 25845968

2

HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients.

Ishihara Y, Harada M, Azuma K, Tamura M, Shomura H, Fujii T, Itoh K, Shichijo S. Ishihara Y, et al. Among authors: harada m. Int J Oncol. 2004 Apr;24(4):967-75. Int J Oncol. 2004. PMID: 15010837

3

Harada M, Matsueda S, Yao A, Ogata R, Noguchi M, Itoh K. Harada M, et al. Oncol Rep. 2004 Sep;12(3):601-7. Oncol Rep. 2004. PMID: 15289844

4

Anti-tumour activity of heat-shock protein 60-recognizing CD4+ T cells against syngeneic murine renal cell carcinoma.

Eto M, Harada M, Tatsugami K, Harano M, Koga H, Matsuzaki G, Naito S. Eto M, et al. Among authors: harada m. BJU Int. 2005 Feb;95(3):421-4. doi: 10.1111/j.1464-410X.2005.05313.x. BJU Int. 2005. PMID: 15679807

5

ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients.

Shichijo S, Ishihara Y, Azuma K, Komatsu N, Higashimoto N, Ito M, Nakamura T, Ueno T, Harada M, Itoh K. Shichijo S, et al. Among authors: harada m. Oncol Rep. 2005 May;13(5):907-13. Oncol Rep. 2005. PMID: 15809757

6

Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.

Hara M, Matsueda S, Tamura M, Takedatsu H, Tanaka M, Kawano K, Mochizuki K, Kamura T, Itoh K, Harada M. Hara M, et al. Among authors: harada m. Int J Oncol. 2005 Nov;27(5):1371-9. Int J Oncol. 2005. PMID: 16211234

7

Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients.

Wang Y, Harada M, Yano H, Ogasawara S, Tanaka M, Yamada A, Itoh K. Wang Y, et al. Among authors: harada m. Oncol Rep. 2006 Feb;15(2):317-21. Oncol Rep. 2006. PMID: 16391848

8

In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.

Ichikura H, Eto M, Ueno H, Harada M, Takayama K, Tokuda N, Tatsugami K, Naito S. Ichikura H, et al. Among authors: harada m. Oncol Rep. 2006 May;15(5):1333-7. Oncol Rep. 2006. PMID: 16596207

9

Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.

Homma S, Harada M, Yano H, Ogasawara S, Shichijo S, Matsueda S, Komatsu N, Shomura H, Maeda Y, Sato Y, Todo S, Itoh K. Homma S, et al. Among authors: harada m. Int J Oncol. 2006 Sep;29(3):577-87. Int J Oncol. 2006. PMID: 16865273

10

Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.

Komohara Y, Harada M, Arima Y, Suekane S, Noguchi M, Yamada A, Itoh K, Matsuoka K. Komohara Y, et al. Among authors: harada m. Int J Oncol. 2006 Dec;29(6):1555-60. Int J Oncol. 2006. PMID: 17088996

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,932 results

Search Page

Filters